News and Updates

Genzyme Receives FDA Approval for Mozobil

The U.S. Food and Drug Administration has granted marketing approval for Mozobil, Genzyme’s patented drug which stimulates the mobilization of autologous adult stem cells, now available for the treatment of non-Hodgkin’s lymphoma and multiple myeloma.

Read More »

Take the first step towards the healthier life you deserve.

The Stem Cell Institute has integrated Intranasal MTF Therapy into its autism protocol:

  • MTF therapy features exosomes and over 300 beneficial molecules
  • Works in synergy with our stem cells
  • Offers anti-inflammatory and regenerative effects
  • Delivered in an easy-to-administer aerosol format via the nose
  • To discover more about MTF and its benefits, click here